TIZIANA LIFE SCIENCES LTD (F:0RP) — Market Cap & Net Worth
Market Cap & Net Worth: TIZIANA LIFE SCIENCES LTD (0RP)
TIZIANA LIFE SCIENCES LTD (F:0RP) has a market capitalization of $157.03 Million (€134.32 Million) as of May 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #17462 globally and #1633 in its home market, demonstrating a -7.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying TIZIANA LIFE SCIENCES LTD's stock price €1.06 by its total outstanding shares 127247401 (127.25 Million). Analyse 0RP operating cash flow to see how efficiently the company converts income to cash.
TIZIANA LIFE SCIENCES LTD Market Cap History: 2019 to 2026
TIZIANA LIFE SCIENCES LTD's market capitalization history from 2019 to 2026. Data shows change from $141.28 Million to $157.69 Million (-1.69% CAGR).
TIZIANA LIFE SCIENCES LTD Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how TIZIANA LIFE SCIENCES LTD's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 0RP by Market Capitalization
Companies near TIZIANA LIFE SCIENCES LTD in the global market cap rankings as of May 4, 2026.
Key companies related to TIZIANA LIFE SCIENCES LTD by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $107.56 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #367 globally with a market cap of $72.88 Billion USD.
- UCB SA (BR:UCB): Ranked #517 globally with a market cap of $51.45 Billion USD ( €44.01 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #568 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $107.56 Billion | $423.92 |
| #367 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.88 Billion | $701.42 |
| #517 | UCB SA | BR:UCB | $51.45 Billion | €231.20 |
| #568 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
TIZIANA LIFE SCIENCES LTD Historical Marketcap From 2019 to 2026
Between 2019 and today, TIZIANA LIFE SCIENCES LTD's market cap moved from $141.28 Million to $ 157.69 Million, with a yearly change of -1.69%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €157.69 Million | -17.19% |
| 2025 | €190.42 Million | +101.57% |
| 2024 | €94.47 Million | +25.74% |
| 2023 | €75.13 Million | -3.81% |
| 2022 | €78.10 Million | -36.36% |
| 2021 | €122.73 Million | -50.10% |
| 2020 | €245.95 Million | +74.09% |
| 2019 | €141.28 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of TIZIANA LIFE SCIENCES LTD was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $157.03 Million USD |
| MoneyControl | $157.03 Million USD |
| MarketWatch | $157.03 Million USD |
| marketcap.company | $157.03 Million USD |
| Reuters | $157.03 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About TIZIANA LIFE SCIENCES LTD
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more